Blog
News & Updates
Stay updated with Dei BioPharma’s latest breakthroughs, milestones, and industry insights in pharmaceutical innovation.
DEI Biopharma Announces Breakthrough CRISPR-Based Gene Therapy Platform for Sickle Cell Disease
KAMPALA, Uganda — Dei BioPharma, a global biotechnology company focused on affordable, next-generation medicines, today announced the development of a CRISPR-based gene...
Dr. Magoola gets FDA boost for rare borne drug in US market
Kampala — Ugandan pharmaceutical manufacturer Dei Biopharma led by scientist Dr. Matthias Magoola has received a significant boost in its...
Museveni launches Dei BioPharma biotech park in Kamuli
KAMULI, Uganda — President Museveni on Thursday November 20, launched the Dei Biopharma Advanced Agro-Processing and Biotech Park in Namasagali,...
Dei BioPharma’s Dr. Magoola unveils new mRNA Ebola and Mpox vaccines at Africa CDC meeting in South Africa
Durban City, South Africa – Dei BioPharma Founder Dr. Matthias Magoola, has announced at a meeting of the African Center...
Museveni praises Dr. Magoola’s leadership of the knowledge economy as he launches 2026 NRM Manifesto
KAMPALA - President Yoweri Museveni has indicated that the Ugandan economy will rip big from the knowledge economy, including biotechnology...
TOP STORY: Dei BioPharma chief Magoola gets US FDA waiver for the clinical trial period for his new cancer therapies
KAMPALA, Uganda — The U.S. Food and Drug Administration (FDA) has agreed to waive clinical efficacy testing requirements for two...
Dei Biopharma founder Dr. Magoola honored with Lifetime Achievement Award in Canada
BRAMPTON, Ontario — Dr. Matthias Magoola, a Ugandan scientist and founder of Dei Biopharma Ltd., has been honored with the...
Dei BioPharma receives second US FDA approval for key diabetes drug
KAMPALA, UGANDA — Dei BioPharma Ltd announced on Tuesday that the U.S. Food and Drug Administration has accepted the development...
News Release
Kampala, Uganda - DEI BioPharma, a leading Ugandan pharmaceutical innovator, has announced a groundbreaking plan to manufacture patent-protected active pharmaceutical ingredients...